These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 8564955)

  • 1. Germ line mutation at BRCA1 affects the histoprognostic grade in hereditary breast cancer.
    Eisinger F; Stoppa-Lyonnet D; Longy M; Kerangueven F; Noguchi T; Bailly C; Vincent-Salomon A; Jacquemier J; Birnbaum D; Sobol H
    Cancer Res; 1996 Feb; 56(3):471-4. PubMed ID: 8564955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Truncation at conserved terminal regions of BRCA1 protein is associated with highly proliferating hereditary breast cancers.
    Sobol H; Stoppa-Lyonnet D; Bressac-de-Paillerets B; Peyrat JP; Kerangueven F; Janin N; Noguchi T; Eisinger F; Guinebretiere JM; Jacquemier J; Birnbaum D
    Cancer Res; 1996 Jul; 56(14):3216-9. PubMed ID: 8764110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathologic analysis of BRCA1- or BRCA2-associated hereditary breast carcinoma in Japanese women.
    Noguchi S; Kasugai T; Miki Y; Fukutomi T; Emi M; Nomizu T
    Cancer; 1999 May; 85(10):2200-5. PubMed ID: 10326698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modification of BRCA1- and BRCA2-associated breast cancer risk by AIB1 genotype and reproductive history.
    Rebbeck TR; Wang Y; Kantoff PW; Krithivas K; Neuhausen SL; Godwin AK; Daly MB; Narod SA; Brunet JS; Vesprini D; Garber JE; Lynch HT; Weber BL; Brown M
    Cancer Res; 2001 Jul; 61(14):5420-4. PubMed ID: 11454686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer: a population-based study in Italy.
    Ottini L; Masala G; D'Amico C; Mancini B; Saieva C; Aceto G; Gestri D; Vezzosi V; Falchetti M; De Marco M; Paglierani M; Cama A; Bianchi S; Mariani-Costantini R; Palli D
    Cancer Res; 2003 Jan; 63(2):342-7. PubMed ID: 12543786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunophenotypic and pathologic differences between BRCA1 and BRCA2 hereditary breast cancers.
    Phillips KA
    J Clin Oncol; 2000 Nov; 18(21 Suppl):107S-12S. PubMed ID: 11060337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival in familial, BRCA1-associated, and BRCA2-associated epithelial ovarian cancer. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) Familial Ovarian Cancer Study Group.
    Pharoah PD; Easton DF; Stockton DL; Gayther S; Ponder BA
    Cancer Res; 1999 Feb; 59(4):868-71. PubMed ID: 10029077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequency of BRCA1 and BRCA2 mutations in a clinic-based series of breast and ovarian cancer families.
    Vaziri SA; Krumroy LM; Rostai M; Casey G
    Hum Mutat; 2001; 17(1):74. PubMed ID: 11139249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The frequency of germ-line mutations in the breast cancer predisposition genes BRCA1 and BRCA2 in familial prostate cancer. The Cancer Research Campaign/British Prostate Group United Kingdom Familial Prostate Cancer Study Collaborators.
    Gayther SA; de Foy KA; Harrington P; Pharoah P; Dunsmuir WD; Edwards SM; Gillett C; Ardern-Jones A; Dearnaley DP; Easton DF; Ford D; Shearer RJ; Kirby RS; Dowe AL; Kelly J; Stratton MR; Ponder BA; Barnes D; Eeles RA
    Cancer Res; 2000 Aug; 60(16):4513-8. PubMed ID: 10969800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindreds.
    Casey MJ; Bewtra C; Hoehne LL; Tatpati AD; Lynch HT; Watson P
    Gynecol Oncol; 2000 Sep; 78(3 Pt 1):278-87. PubMed ID: 10985881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characteristics of small breast and/or ovarian cancer families with germline mutations in BRCA1 and BRCA2.
    Ligtenberg MJ; Hogervorst FB; Willems HW; Arts PJ; Brink G; Hageman S; Bosgoed EA; Van der Looij E; Rookus MA; Devilee P; Vos EM; Wigbout G; Struycken PM; Menko FH; Rutgers EJ; Hoefsloot EH; Mariman EC; Brunner HG; Van 't Veer LJ
    Br J Cancer; 1999 Mar; 79(9-10):1475-8. PubMed ID: 10188893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CAG and GGC repeat polymorphisms in the androgen receptor gene and breast cancer susceptibility in BRCA1/2 carriers and non-carriers.
    Kadouri L; Easton DF; Edwards S; Hubert A; Kote-Jarai Z; Glaser B; Durocher F; Abeliovich D; Peretz T; Eeles RA
    Br J Cancer; 2001 Jul; 85(1):36-40. PubMed ID: 11437399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention and therapy for BRCA1/2 mutation carriers and women at high risk for breast and ovarian cancer.
    Kuschel B; Lux MP; Goecke TO; Beckmann MW
    Eur J Cancer Prev; 2000 Jun; 9(3):139-50. PubMed ID: 10954253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A high occurrence of BRCA1 and BRCA2 mutations among Czech hereditary breast and breast-ovarian cancer families.
    Machácková E; Foretová L; Navrátilová M; Valík D; Claes K; Messiaen L
    Cas Lek Cesk; 2000 Oct; 139(20):635-7. PubMed ID: 11192759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study.
    Hopper JL; Southey MC; Dite GS; Jolley DJ; Giles GG; McCredie MR; Easton DF; Venter DJ
    Cancer Epidemiol Biomarkers Prev; 1999 Sep; 8(9):741-7. PubMed ID: 10498392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A probability model for predicting BRCA1 and BRCA2 mutations in breast and breast-ovarian cancer families.
    Vahteristo P; Eerola H; Tamminen A; Blomqvist C; Nevanlinna H
    Br J Cancer; 2001 Mar; 84(5):704-8. PubMed ID: 11237395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutations at BRCA1: the medullary breast carcinoma revisited.
    Eisinger F; Jacquemier J; Charpin C; Stoppa-Lyonnet D; Bressac-de Paillerets B; Peyrat JP; Longy M; Guinebretière JM; Sauvan R; Noguchi T; Birnbaum D; Sobol H
    Cancer Res; 1998 Apr; 58(8):1588-92. PubMed ID: 9563465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2.
    Lakhani SR; Gusterson BA; Jacquemier J; Sloane JP; Anderson TJ; van de Vijver MJ; Venter D; Freeman A; Antoniou A; McGuffog L; Smyth E; Steel CM; Haites N; Scott RJ; Goldgar D; Neuhausen S; Daly PA; Ormiston W; McManus R; Scherneck S; Ponder BA; Futreal PA; Peto J; Stoppa-Lyonnet D; Bignon YJ; Stratton MR
    Clin Cancer Res; 2000 Mar; 6(3):782-9. PubMed ID: 10741697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
    Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
    Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRCA-associated breast cancer: absence of a characteristic immunophenotype.
    Robson M; Rajan P; Rosen PP; Gilewski T; Hirschaut Y; Pressman P; Haas B; Norton L; Offit K
    Cancer Res; 1998 May; 58(9):1839-42. PubMed ID: 9581822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.